Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
28.01
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.3
Face value
--
Shares outstanding
16,519,300
CFO
$-168.86 Mln
EBITDA
$-173.99 Mln
Net Profit
$-190.78 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ibio Inc (IBIO)
| -69.5 | -8.6 | -83.8 | -64.4 | -83.1 | -74.7 | -58.6 |
|
BSE Sensex*
| 5.6 | 1.1 | 6.0 | 6.8 | 16.2 | 18.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Ibio Inc (IBIO)
| 78.0 | -84.6 | -96.8 | -47.6 | 321.7 | -66.9 | -57.3 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ibio Inc (IBIO)
|
0.7 | 11.6 | 0.4 | -21.0 | -4,328.5 | -144.1 | -- | 1.1 |
| 17.9 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 8.1 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 104.3 | 5,004.9 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 93.2 | |
| 54.7 | 10,371.3 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20 | 1.8 | |
| 44.5 | 8,008.2 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 76.8 | 7,877.0 | 685.5 | 132.9 | 15.6 | 20.1 | 64.6 | 11.1 | |
| 13.5 | 6,630.2 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.8 | 1.1 | |
| 84.7 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.2 | |
| 9.0 | 10,387.1 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3... T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 11750 Sorrento Valley Road, San Diego, CA, United States, 92121 Read more
CEO & Chief Scientific Officer
Dr. Martin B. Brenner D.V.M., Ph.D.
Chief Financial Officer
Mr. Felipe Duran
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ibio Inc (IBIO) stood at $ 25 Mln as on 31-Mar-25
The share price of Ibio Inc (IBIO) is $0.75 (NYSE) as of 24-Jun-2025 16:29 EDT. Ibio Inc (IBIO) has given a return of -83.14% in the last 3 years.
Ibio Inc (IBIO) has a market capitalisation of $ 12 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Ibio Inc (IBIO) is 1.10 times as on 24-Jun-2025, a 77% discount to its peers’ median range of 4.72 times.
Since, TTM earnings of Ibio Inc (IBIO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ibio Inc (IBIO) and enter the required number of quantities and click on buy to purchase the shares of Ibio Inc (IBIO).
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 11750 Sorrento Valley Road, San Diego, CA, United States, 92121
The CEO & director of Dr. Martin B. Brenner D.V.M., Ph.D.. is Ibio Inc (IBIO), and CFO & Sr. VP is Mr. Felipe Duran.
There is no promoter pledging in Ibio Inc (IBIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| Ibio Inc (IBIO) | Ratios |
|---|---|
|
Return on equity(%)
|
-144.1
|
|
Operating margin(%)
|
-4328.53
|
|
Net Margin(%)
|
-5597.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ibio Inc (IBIO) was $0 Mln.
$0.02
(
